Experimental immune therapy takes on tough lymphomas
NCT ID NCT05963217
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new cell therapy called TBI-2001 for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to find a safe dose and to see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TBI-2001 (a CAR T-cell therapy made from the patient's own immune cells, designed to target and kill cancer cells with the CD19 marker)
- What this could lead to
- If this works, it could offer a new treatment option for people with certain blood cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 19 participants, so it is primarily testing safety and dosing. The therapy may not work, and there are risks of serious side effects like cytokine release syndrome or nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY CD19+ B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Italian study tracks how venetoclax works for CLL patients in everyday practice
- New hope for tough blood cancers: early trial of ONO-7018 begins
- New drug combo takes aim at High-Risk leukemia
- New 'Quad-Specific' antibody tackles tough leukemia
- New pill shows promise for Hard-to-Treat blood cancers in japanese patients